About The Study: Zerlasiran, a small-interfering RNA targeting hepatic synthesis of apolipoprotein(a), was well-tolerated and reduced time-averaged lipoprotein(a) concentration by more than 80% during 36 weeks of treatment in patients with atherosclerotic cardiovascular disease.
Corresponding Author: To contact the corresponding author, Steven E. Nissen, MD, email nissens@ccf.org .
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2024.21957)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Media advisory: This study is being presented at the American Heart Association’s Scientific Sessions 2024.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.21957?guestAccessKey=f0dc38dc-63c0-41f5-a731-77e1e406f2ab&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=111824
JAMA